摘要
塞利尼索是首个核输出蛋白1抑制剂,已被美国食品药品监督管理局和中国国家药品监督管理局批准用于复发难治多发性骨髓瘤、弥漫大B细胞淋巴瘤的治疗。自2022年版塞利尼索在血液系统疾病中的临床应用指导原则发布后,国内外有关塞利尼索在多发性骨髓瘤、B/T细胞淋巴瘤、骨髓纤维化、急性髓系白血病、骨髓增生异常综合征领域的研究数据不断更新。为给我国血液科医生提供更加规范化的临床实践指导,专家组成员经过充分讨论并汇总国内外权威指南和文献,对指导原则进行了更新。
Selinexor,the first exportin-1 inhibitor,has been approved by the US Food and Drug Administration and the China's National Medical Products Administration for the treatment of relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma.Since the publication of the principles for clinical application of selinexor in hematological system diseases(2022 version),domestic and international research data on selinexor in the fields of multiple myeloma,B/T-cell lymphoma,myelofibrosis,acute myeloid leukemia,and myelodysplastic syndromes have been continuously updated.In order to provide standardized clinical practice guidance for the Chinese hematologists,the expert group members have thoroughly discussed and summarized the authoritative guidelines and literature at home and abroad,and updated the guiding principles.
出处
《白血病.淋巴瘤》
2025年第5期269-283,共15页
Journal of Leukemia & Lymphoma
